Product: Estradiol (cypionate)
CEACAM6/CD66c Antibody Summary
| Immunogen |
Synthetic peptide directed towards the middle region of human CEACAM6 (NP_002474). Peptide sequence: EIQNPASANRSD
|
| Clonality |
Polyclonal
|
| Host |
Rabbit
|
| Gene |
CEACAM6
|
| Purity |
Protein A purified
|
| Innovators Reward |
Test in a species/application not listed above to receive a full credit towards a future purchase.
Learn about the Innovators Reward
|
Applications/Dilutions
| Dilutions |
|
| Application Notes |
This is a rabbit polyclonal antibody against CEACAM6 and was validated on Western Blot and immunohistochemistry-P The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
|
| Theoretical MW |
38 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors. |
Packaging, Storage & Formulations
| Storage |
Store at -20C. Avoid freeze-thaw cycles.
|
| Buffer |
PBS and 2% Sucrose
|
| Preservative |
0.09% Sodium Azide
|
| Purity |
Protein A purified
|
Notes
The addition of 50% glycerol is optional for those storing this antibody at -20C and not aliquoting smaller units. However, please note that glycerol may interrupt some downstream antibody applications and should be added with caution.
Alternate Names for CEACAM6/CD66c Antibody
- carcinoembryonic antigen-related cell adhesion molecule 6 (non-specific crossreacting antigen)
- carcinoembryonic antigen-related cell adhesion molecule 6
- CD66c antigen
- CD66c
- CEACAM6
- CEACAM-6
- CEAL
- NCA
- NCACEAL
- Non-specific crossreacting antigen
- Normal cross-reacting antigen
Background
Many breast, pancreatic, colonic and non-small-cell lung carcinoma lines express CEACAM6 and CEACAM5, and antibodies to both can affect tumor cell growth in vitro and in vivo. CEACAM6 expression is elevated in many solid tumors, but variable as a function of histotype. It may be a promising target for antibody-based therapy.